reviewSignal Transduction and Targeted TherapyJul 3, 2025GOLD OA

CAR-T cell therapy for cancer: current challenges and future directions

IZInés ZugastiLELady Espinosa-ArocaKFKlaudyna FidytVMVladimir Mulens‐AriasMDMarina Díaz‐Beyá

Josep Carreras Leukaemia Research Institute · Red de Investigación en Sida · +11 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

Chimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment of relapsed/refractory (R/R) B-cell malignancies and multiple myeloma by redirecting activated T cells to CD19- or BCMA-expressing tumor cells. However, this approach has yet to be approved for acute myeloid leukemia (AML), the most common acute leukemia in adults and the elderly. Simultaneously, CAR-T cell therapies continue to face significant challenges in the treatment of solid tumors. The primary challenge in developing CAR-T cell therapies for AML is the absence of an ideal target antigen that is both effective and safe, as AML cells share most surface antigens with healthy hematopoietic stem and progenitor cells (HSPCs).…

Citation impact

156
total citations
FWCI
124.17
Percentile
100%
References
537
Citations per year

Authors

10

Topics & keywords

Topics
Keywords
  • Chimeric antigen receptor
  • Medicine
  • Cancer research
  • Progenitor cell
  • Myeloid leukemia
  • Cell therapy
  • Antigen
  • CD19
No related works found for this paper.

Funding